Presented at AACR and EACR 2023
The B-NDG (Biocytogen; NOD; DNAPK null; IL2rg knockout) mouse model was developed to be an ideal testing platform for anti-tumor therapies in cell-line and patient derived xenograft models (CDX and PDX respectively).
Gain insights about the B-NDG mouse that can help you decide whether it is the optimal mouse for your immunotherapy program.
Download your copy to:
-
Understand the development rationale for the B-NDG B2M KO plus model
-
Review the B-NDG B2M model characterization study data
-
Realize the benefits of the model in cancer immunotherapy research
